- Home
- NUVL vs UEC Comparison
NUVL vs UEC Comparison
Compare NUVL & UEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- UEC
- Stock Information
- Founded
- NUVL 2017
- UEC 2003
- Country
- NUVL United States
- UEC United States
- Employees
- NUVL N/A
- UEC N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- UEC Other Metals and Minerals
- Sector
- NUVL Health Care
- UEC Basic Materials
- Exchange
- NUVL Nasdaq
- UEC Nasdaq
- Market Cap
- NUVL 5.8B
- UEC 4.8B
- IPO Year
- NUVL 2021
- UEC N/A
- Fundamental
- Price
- NUVL $80.89
- UEC $11.16
- Analyst Decision
- NUVL Strong Buy
- UEC Strong Buy
- Analyst Count
- NUVL 11
- UEC 4
- Target Price
- NUVL $120.91
- UEC $11.06
- AVG Volume (30 Days)
- NUVL 429.4K
- UEC 12.4M
- Earning Date
- NUVL 08-07-2025
- UEC 09-26-2025
- Dividend Yield
- NUVL N/A
- UEC N/A
- EPS Growth
- NUVL N/A
- UEC N/A
- EPS
- NUVL N/A
- UEC N/A
- Revenue
- NUVL N/A
- UEC $66,837,000.00
- Revenue This Year
- NUVL N/A
- UEC $34,840.18
- Revenue Next Year
- NUVL N/A
- UEC $14.29
- P/E Ratio
- NUVL N/A
- UEC N/A
- Revenue Growth
- NUVL N/A
- UEC 70.62
- 52 Week Low
- NUVL $55.54
- UEC $3.85
- 52 Week High
- NUVL $113.51
- UEC $11.80
- Technical
- Relative Strength Index (RSI)
- NUVL 61.76
- UEC 64.38
- Support Level
- NUVL $73.28
- UEC $10.12
- Resistance Level
- NUVL $81.10
- UEC $11.80
- Average True Range (ATR)
- NUVL 2.51
- UEC 0.61
- MACD
- NUVL 0.77
- UEC 0.01
- Stochastic Oscillator
- NUVL 83.27
- UEC 75.10
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About UEC Uranium Energy Corp.
Uranium Energy Corp is engaged in uranium mining and related activities. The company is working towards fueling the demand for carbon-free nuclear energy, a key solution to climate change, and energy source for the low-carbon future. The company is advancing its next generation of low-cost, environmentally friendly, in-situ recovery (ISR) mining uranium projects. The company has two extraction-ready ISR hub and spoke platforms in South Texas and Wyoming. UEC also has seven U.S. ISR uranium projects with all of their permits in place, with additional diversified holdings of uranium assets across the U.S., Canada and Paraguay.